Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations Chromosomal translocations of the mixed-lineage leukemia (MLL) gene are common genetic events in acute leukemias. In acute myeloid leukemia (AML), the translocation t(9;11)(p22;q23) [subsequently referred to as t(9;11)] resulting in the MLL-MLLT3-fusion protein is the most common translocation involving MLL. Translocation (9;11) can be found in both, de novo and therapy-related AML (t-AML) and the current WHO classification separates these two subtypes into distinct categories(1). De novo and t-AML generally differ in terms of treatment response and survival with therapy-related cases being associated with inferior outcome and abnormal and more complex cytogenetics(1, 2). However, little is known about the biological and clinical difference between de novo and therapy-related MLL-MLLT3-rearranged AML.
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The exposure to chemo-/radiation therapy as it occurs in t-AML is hypothesized to alter the number of copy number alterations (CNAs) that could potentially reflect biological differences between these AML subtypes. Furthermore, cooperating genetic events are discussed to be required for MLL-leukemogenesis, since knock-in mice that express the
MLL-MLLT3-fusion gene under control of the MLL promoter develop AML with a leukemia onset after 4 months to >1 year(3).
To explore number and type of cooperating genetic lesions in AML with t(9;11), we performed SNP-array based genotyping of 40 diagnostic leukemia samples from de novo and t-AML patients [de novo, n=22; t-AML, n=16, unknown, n=2; Table S1 ]. Intra-individual germline DNA from remission bone marrow or peripheral blood was available for paired analysis in 15 cases. From the unpaired cohort only those lesions were considered as truly somatically acquired that were found to be altered in at least one sample from the paired cohort in order to minimize false positive calls. SNP-array [GeneChip Human Mapping 6.0 (Affymetrix)] based genotyping and data analysis was performed as previously described (4) .
Raw data were made publicly available at NCBI's Gene Expression Omnibus (series accession number: GSE46745).
Paired analysis of the 15 cases revealed few somatic genetic alterations with only 1.73 CNAs per case (range 0-13). Deletions were more common than gains (de novo: 0.75 losses/case vs. 0.38 gains/case; t-AML: 2.29 losses/case vs. 0.14 gains/case, all mean) and 53% of all cases lacked any detectable CNAs (de novo: 50%; t-AML: 57%). Notably, no significant difference was observed in the mean number of CNAs between de novo and t-AML (de novo: 1.13/case vs. t-AML: 2.43/case, p=0.78). Only one single t-AML case exhibited 13 CNAs (case MLL#3; Table S2 ). These findings clearly distinguish t-AML with t(9;11) from other t-AML entities that frequently exhibit additional chromosomal alterations(2), although the statistical power of this analysis might be limited by the small collection of paired samples. The relatively small number of CNAs in de novo cases is consistent with prior reports on distinct types of de novo AML(5) and MLL-AF4-rearranged acute lymphoblastic leukemia (ALL)(6) but stands in clear contrast to most other ALL subtypes (7) .
Despite the small number of CNAs identified we were able to detect several recurrent lesions (Table 1 , S2, and S3). The most common cytogenetic event was trisomy 8 detected in 20% of the 40 cases (de novo: 27%; t-AML: 6%; p=0.21; Table 1 , Fig.1A ). Besides focal recurrent deletions and gains adjacent to the genes involved in t(9;11) ( Table 1) we identified two novel minimally altered regions (MARs) at chromosomal bands 7q36.1-q36.2 (loss: 5%;
de novo: 5%; t-AML: 6%) and 13q21.33-q22.1 (gain: 5%; de novo: 5%; t-AML: 6%; Table 1 ).
Both regions contain genes whose alterations may cooperate with the translocation-encoded MLL-MLLT3-fusion protein to induce overt leukemia. Del(7q) is a recurrent alteration frequently seen in t-AML and complex karyotype AML but also occurs in other AML subtypes such as the Core-Binding Factor (CBF)-AMLs (4, 8) . The identified MAR at 7q36 contains only 6 genes (Table 1 and Fig.1B ) and is partly overlapping with the MAR that we previously described at 7q36.1 in CBF-AMLs(4). Of note, the overlapping region contained only the MLL3 gene. MLL3 is one of five members of the MLL gene family that encode H3K4 methyltransferases with homology to the Drosophila-trithorax gene and have all been implicated in cancer (9) . The gain(13)(q21.33-q22.1) affected six genes (Table 1, Fig.1C ). Of these, the two genes DIS3 and KLF5 were previously implicated in oncogenesis. KLF5 is a member of the krüppel-like factor transcription factor family critically involved in regulation of cell proliferation and differentiation (10) . It promotes cell proliferation in various tissue types such as gastrointestinal epithelial cells and embryonic stem cells (11) and is found to be reported data demonstrating EVI1 to be essential for tumor growth in a subset of MLL-MLLT3-rearranged AMLs (15). However, with regard to number or type of CNA we did not find substantial differences between EVI1 high and low expression cases (Table S2, S3) .
Based on this observation we cannot propose an increase of genomic complexity as the consequence of the interaction between MLL and EVI1.
In summary, our study demonstrates that CNAs occur at a very low frequency in t(9;11)-positive AML. However, we discovered novel recurrently altered regions that point to potential cancer disease genes. With regard to CNAs we found no differences in number or type of lesions between de novo and t-AML with t(9;11), calling into question the current WHO classification which separates them into different categories. Further clinical outcome data are needed to address this issue. 
MAR=minimally altered region.*hg18. Genes previously reported as oncogenes/tumor suppressor genes and/or listed within the Network of Cancer Genes (NCG 3.0) are highlighted in bold. and local ethics committee approval was available for all patients. The t(9;11) was identified by conventional cytogenetics and/or reverse-transcriptase PCR as previously described (Table S1 )(1).
DNA extraction
Peripheral blood or bone marrow samples obtained at diagnosis and during remission were enriched for leukemic blasts using Ficoll gradient centrifugation as described previously(2, 3).
Cells were stored at -80°C or -196°C, respectively. DNA extraction was performed using the Allprep DNA/RNA mini kit (Qiagen, Leiden). DNA quality and integrity was assessed using a Nanodrop ND-1000 spectrophotometer (Wilmington, DE).
Single-nucleotide polymorphism (SNP)-array-based genotyping
DNA from each sample was processed using Nsp I and Sty I restriction enzymes according to manufacturer's instruction protocol for Affymetrix SNP 6.0 arrays. SNP genotype calls were generated by applying the birdseed algorithms in Genotyping console v2.0, v3.0, v4.0 (Affymetrix) using at least 50 arrays in each analysis. CHP-and CEL-file raw data were processed according to previously described algorithms using reference alignment(4), dChipSNP(5), and circular binary segmentation (CBS) (6) . CBS results were filtered to eliminate all lesions with less than 5 consecutive markers (SNP and/or copy number variants) and with mean segment deviation above 0.2 for gains and below -0.2 for genomic losses. Pair-wise segmentation was performed for each diagnostic sample with matched remission sample. For patient samples lacking any matched material we computed the segmentation against a reference pool of 300 samples from our local database as previously described (2) . From the unpaired cohort only those lesions were counted as truly somatically acquired that were found to be altered in at least one sample from the paired sample cohort.
All other lesions were eliminated from the data set. All calls were also visually inspected using dChipSNP and crosschecked against public databases of copy number polymorphisms (http://projects.tcag.ca/variation/ and http://www.genome.ucsc.edu/) to exclude inherited copy number variants and false calls due to experimental artefacts (inter-batch effects or noise).
For the detection of true copy-neutral loss-of-heterozygosity a threshold of >20 Mb in size and/or with >20 consecutive markers containing less than 10% intervening or conflicting calls was defined according to prior experiences(2, 7).
Gene mutation and gene expression analysis
Gene mutation/expression status was determined for a set of genes known to be frequently Mutation/expression assays were performed as previously described (8, 9) . 
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Statistical analysis
The Kaplan-Meier method, the Wilcoxon rank order-, and the Fisher's exact test were used for calculation of distribution estimation and survival distributions of overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). Definition of complete remission (CR) and survival endpoints such as OS, EFS, and RFS followed the recommended consensus criteria(11). [11] 52,XX,+3,+6,+8,t(9;11)(p22;q23),+12,+13,+18 [9] The t(9;11) was identified by conventional cytogenetics and/or reverse-transcriptase PCR. 
Figure S1
Higher KLF5 expression was associated with lower overall survival as shown (p=0.02, logrank test).
